Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 31.1% in the second quarter, HoldingsChannel reports. The institutional investor owned 183,941 shares of the biopharmaceutical company’s stock after purchasing an additional 43,614 shares during the period. Mutual of America Capital Management LLC’s holdings in Halozyme Therapeutics were worth $9,631,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in HALO. Rise Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $25,000. Whittier Trust Co. acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at $27,000. GAMMA Investing LLC increased its holdings in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at $33,000. Finally, Principal Securities Inc. acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at $34,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $803,876.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the transaction, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nicole Labrosse sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares in the company, valued at approximately $803,876.40. The disclosure for this sale can be found here. Insiders sold 84,881 shares of company stock valued at $4,888,184 in the last quarter. Company insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on HALO. JPMorgan Chase & Co. lowered their price target on Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a report on Friday, September 13th. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley upped their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $59.44.

Halozyme Therapeutics Trading Up 0.6 %

Shares of NASDAQ:HALO opened at $62.31 on Thursday. The stock has a market capitalization of $7.93 billion, a price-to-earnings ratio of 25.75, a PEG ratio of 0.57 and a beta of 1.28. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $65.53. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The company has a 50 day moving average price of $58.14 and a 200 day moving average price of $48.95.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. During the same quarter last year, the business posted $0.68 EPS. The company’s revenue was up 4.7% on a year-over-year basis. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.